Short radiation plus combo drugs for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced rectal adenocarcinoma (a type of rectal cancer that has spread nearby but not far).
- You are between 18 and 75 years old.
- Your overall health is good enough to be up and about (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver, blood clotting) are within safe ranges.
- You have not had immunotherapy before for this cancer.
- You are not pregnant, breastfeeding, or planning pregnancy during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (ivonescimab) for people with locally advanced rectal cancer. It aims to see if this approach can shrink tumors before surgery, especially for high-risk cases.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
This trial tests a new combination of radiation and drugs for people with a type of rectal cancer that has not spread. The goal is to shrink the tumor before surgery, using a shorter course of radiation followed by several medicines.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.